Prelude Therapeutics Inc (PRLD) Financial Statements
Prelude Therapeutics Inc (PRLD) reported trailing twelve-month revenue of $22.4M (up 220.3% year on year) and net income of -$60.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$33.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PRLDPrelude Therapeutics IncFollow PRLD — free
—
Price chart with a free account
- Market cap
- 289.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 7.0 | 12.1 | 22.4 | |
| Research & development | 118.0 | 94.3 | 69.4 | |
| Operating income | -139.7 | -104.6 | -67.4 | |
| Pre-tax income | -127.2 | -99.5 | -60.5 | |
| Income tax | — | 0.0 | — | |
| Net income | -127.2 | -99.5 | -60.5 | |
| Diluted EPS ($) | -1.68 | -1.29 | -0.62 | |
| Diluted shares (mn) | 75.8 | 77.0 | — |
USD millions · SEC XBRL
Prelude Therapeutics Inc — questions
- What is Prelude Therapeutics Inc's revenue?
- $22.4M over the twelve months to 2026-06-30, up 220.3% year on year, from its 10-Q and 10-K filings.
- What is Prelude Therapeutics Inc's net income?
- -$60.5M over the twelve months to 2026-06-30.
- What is Prelude Therapeutics Inc's free cash flow?
- -$33.3M over the twelve months to 2026-06-30.
- What are Prelude Therapeutics Inc's diluted earnings per share?
- $-0.62 over the twelve months to 2026-06-30.
Every figure on this page comes from Prelude Therapeutics Inc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.